A wooly area
Article Abstract:
KS Biomedix is a UK drug developer traded on the Alternative Investment Market. The company is carrying out research on monoclonal antibodies og sheep, to help develop drugs that allow cancer treatments to work more efficiently. The company is also carrying out work on two drugs to treat arthritis. This could result in a link with a large drugs company for further trials, and licensing income from 1997. The company also holds a stake of 75% in a JV for a private cancer hospital in Malaysia.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Roche
Article Abstract:
Roche is a Swiss drugs company that has produced reliable earnings growth. The group's dividend has been less than expected, though investors tend not to hold Roche stock for income, and retention should help capital growth. Roche is likely to carry out an acquisition due to its financial strength, and the previous acquisition of Syntex has produced clear benefits. A rise in value of the US dollar should help Roche, and the group should see solid earnings for 1996.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
KS Biomedix
Article Abstract:
KS Biomedix is using unproven sheep antibody technology, which offers some advantages. The company's stocks are illiquid, which could become a problem.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic: